UTRS
Q4 2026 EPS Estimate
$-5.92
Nov 17, 2026
Revenue Estimate
$13M

Analyst Sentiment

Wall St. Consensus
Buy
4 analysts·Low coverage
63
Score
3 Buy (75%)0 Hold (0%)1 Sell (25%)
Rating Breakdown
Strong Buy
00%
Buy
375%
Hold
00%
Sell
125%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$100.00
+99999900.0%
Consensus
$100.00
+99999900.0%
Bull
$100.00
+99999900.0%
12-Month Target Range4 analysts
$100.00$100.00$100.00
Current $0.00Consensus
Current Price
$0.00
Upside to Consensus
$100.00

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Raw consensus estimates (low / average / high) from covering analysts.
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$13M$11M$13M$13M$15M$12M$14M$13M
Low$13M$11M$13M$13M$15M$12M$14M$13M
High$13M$11M$13M$13M$15M$12M$14M$13M
EBITDA Avg$-3M$-3M$-3M$-3M$-4M$-3M$-4M$-3M
Low$-3M$-3M$-3M$-3M$-4M$-3M$-4M$-3M
High$-3M$-3M$-3M$-3M$-4M$-3M$-4M$-3M
EBIT Avg$-6M$-5M$-6M$-5M$-6M$-5M$-6M$-6M
Low$-6M$-5M$-6M$-5M$-6M$-5M$-6M$-6M
High$-6M$-5M$-6M$-5M$-6M$-5M$-6M$-6M
Net Income Avg$-53M$-55M$-60M$-50M$-50M$-20M$-16M$-9M
Low$-53M$-55M$-60M$-50M$-50M$-20M$-16M$-9M
High$-53M$-55M$-60M$-50M$-50M$-20M$-16M$-9M
EPS Avg$-5.92$-6.19$-6.79$-5.60$-5.60$-2.20$-1.80$-1.00
Low$-5.92$-6.19$-6.79$-5.60$-5.60$-2.20$-1.80$-1.00
High$-5.92$-6.19$-6.79$-5.60$-5.60$-2.20$-1.80$-1.00
Analysts (Rev / EPS)1 / 11 / 11 / 11 / 11 / 11 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Aug 9, 2022Piper Sandler
Minerva Surgical price target lowered to $5 from $6 at Piper Sandler
Target:$5.00
-90.7%from $53.80
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.